Expression of HIV-1 integrase in CEM cells inhibits HIV-1 replication
✍ Scribed by Johan van Griensven; Xiaojing Zhan; Bénédicte Van Maele; Wim Pluymers; Martine Michiels; Erik De Clercq; Peter Cherepanov; Zeger Debyser
- Publisher
- John Wiley and Sons
- Year
- 2004
- Tongue
- English
- Weight
- 247 KB
- Volume
- 6
- Category
- Article
- ISSN
- 1099-498X
- DOI
- 10.1002/jgm.520
No coin nor oath required. For personal study only.
✦ Synopsis
Abstract
Background
HIV‐1 integrase (IN) is an interesting target for the gene therapy of AIDS. Although the in vivo functions are not well characterized, it is thought that IN has pleiotropic effects and plays a central role in the interplay between the virus and the host cell. Expression of IN in mammalian cells has proven difficult. We have previously established a 293T‐derived cell line that stably expresses high levels of HIV‐1 IN from a synthetic gene. We now have constructed CEM‐derived cell lines stably expressing the enzyme or its different domains and studied the impact of IN expression on HIV‐1 replication.
Methods
The CEM cell lines were selected following transduction with a retroviral vector encoding the full‐length IN, the N‐terminal domain, the catalytic core or the C‐terminal domain. Stable IN expression in CEM cell lines was verified by Western blotting. The impact of IN expression on HIV‐1 replication and HIV‐1 vector transduction was studied.
Results
A marked inhibitory effect on HIV‐1 replication was observed in CEM cells expressing IN. Expression of IN interfered with both particle production and integration. Expression of the N‐terminal domain alone was sufficient for the inhibiting of HIV‐1 replication.
Conclusions
Expression of IN in CEM cells inhibits HIV‐1 replication by a cumulative inhibitory effect on integration and particle production, in accord with the known pleiotropic interactions of IN. The inhibition of HIV‐1 replication in CEM cells expressing the N‐terminal domain of IN may lead to a novel approach for the gene therapy of AIDS. Copyright © 2004 John Wiley & Sons, Ltd.
📜 SIMILAR VOLUMES
## Abstract The HIV‐1 Integrase protein (IN) mediates the integration of the viral cDNA into the host genome. IN is an emerging target for anti‐HIV drug design, and the first IN‐inhibitor was recently approved by the FDA. We have developed a new approach for inhibiting IN by “shiftides”: peptides d
HIV-1 and HIV-2 are co-endemic in certain geographic areas. HIV-2 is more weakly pathogenic than HIV-1, and progression to AIDS occurs less frequently and over a longer period of time. Recent epidemiologic studies suggest that individuals infected with HIV-2 have a lower risk of HIV-1 infection. Bot